Get 20% Off Journals at LWW.com

Low-molecular-weight heparin use with thrombolysis: is it effective and safe? Ten years' clinical experience.

Respiration 2013 9;86(4):318-23. Epub 2013 Feb 9.

Department of Pulmonary Diseases, Ataturk University School of Medicine, Erzurum, Turkey.

Background: There is no data on the use of subcutaneous low-molecular-weight heparin (SC LMWH) in cases that require thrombolysis.

Objective: Having used SC LMWH with thrombolytics for more than 10 years, we aimed to review our data, share our experiences and find out whether the use of SC LMWH with thrombolytics had been effective and safe.

Method: This is a retrospective cohort study. Patients who were diagnosed as acute pulmonary embolism (PE) and received either SC LMWH treatment or SC LMWH with thrombolytics in our hospital (a tertiary hospital) between 2000 and 2010 were included in the study. For both treatments, the rates of mortality and complications were calculated.

Results: A total of 392 patients, 210 female (53.5%) and 182 male (46.5%) with an average age of 60 years, ±16 SD, with acute PE, were included in the study. Of these patients, 107 (27.2%) were massive and 285 (72.8%) were nonmassive and were administered SC LMWH plus thrombolytics and only SC LMWH, respectively. The mortality rate was 16.8% (18 of 107) in patients who were massive and 3.5% (10 of 285) for those who were nonmassive (p < 0.001). Major hemorrhage occurred in 3.7% (n = 4) and 0.7% (n = 2) and minor hemorrhage in 12.1% (n = 13) and in 3.8% (n = 11) of the cases who received SC LMWH plus thrombolytics and SC LMWH, respectively.

Conclusion: SC LMWH use with thrombolytics seems to be feasible and safe. Prospective, large, randomized control trials are still required in order to confirm these results.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000346203DOI Listing
August 2014
Get 20% Off Journals at LWW.com

Similar Publications

Anticoagulant management by low-dose of low molecular weight heparin in patients with nonvalvular atrial fibrillation following hemorrhagic transformation and complicated with venous thrombosis: Five case reports and literature review.

Medicine (Baltimore) 2021 Feb;100(7):e24189

Department of Rehabilitation, The First Affiliated Hospital of Chongqing Medical University, Yuzhong District, Chongqing City, China.

Abstract: For patients with nonvalvular atrial fibrillation (NVAF) following hemorrhagic infarction (HI)/hemorrhage transformation (HT) and complicated with venous thrombosis, the management of anticoagulation is controversial. Our study intends to explore the safety and effectiveness of using low-dose of low molecular weight heparin (LMWH) to treat NVAF patients with HI (or HT) and complicated with venous thrombosis.Between January 2018 and January 2019, NVAF related acute ischemic stroke patients with HT/HI, hospitalized in the department of neurology or rehabilitation in our hospital, are enrolled retrospectively. Read More

View Article and Full-Text PDF
February 2021

[Basics and Clinics of Cancer-Associated Venous Thromboembolism].

Gan To Kagaku Ryoho 2021 Feb;48(2):165-169

Division of Lower GI, Dept. of Gastroenterological Surgery, Hyogo College of Medicine.

Cancer patients, especially active cancer patients have high risk of cancer-associated venous thromboembolism(VTE). Virchow's triad, hyper-coagulability, endothelial cell damage, and blood stasis are often found during cancer treatment. Tissue factor expressed on tumor cells activate coagulation, and decrease in antithrombotic activity by topical inflammation and platelet activation increase the risk of VTE. Read More

View Article and Full-Text PDF
February 2021

Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study.

BMJ 2021 02 11;372:n311. Epub 2021 Feb 11.

Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

Objective: To evaluate whether early initiation of prophylactic anticoagulation compared with no anticoagulation was associated with decreased risk of death among patients admitted to hospital with coronavirus disease 2019 (covid-19) in the United States.

Design: Observational cohort study.

Setting: Nationwide cohort of patients receiving care in the Department of Veterans Affairs, a large integrated national healthcare system. Read More

View Article and Full-Text PDF
February 2021

Therapeutic Potential of Resveratrol in COVID-19-Associated Hemostatic Disorders.

Molecules 2021 Feb 6;26(4). Epub 2021 Feb 6.

Department of Medical Laboratory Sciences, College of Health Sciences, and Sharjah Institute for Medical Research, University of Sharjah, University City Rd, Sharjah 27272, United Arab Emirates.

Coagulation disorders, endotheliopathy and inflammation are the most common hallmarks in SARS-CoV-2 infection, largely determining COVID-19's outcome and severity. Dysfunctions of endothelial cells and platelets are tightly linked in contributing to the systemic inflammatory response that appears to be both a cause and a consequence of COVID-19-associated coagulation disorders and thrombotic events. Indeed, elevated levels of circulating inflammatory cytokines are often associated with abnormal coagulation parameters in COVID-19 patients. Read More

View Article and Full-Text PDF
February 2021

American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19.

Blood Adv 2021 02;5(3):872-888

Michael G. DeGroote Cochrane Canada Centre.

Background: Coronavirus disease 2019 (COVID-19)-related critical illness and acute illness are associated with a risk of venous thromboembolism (VTE).

Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in decisions about the use of anticoagulation for thromboprophylaxis for patients with COVID-19-related critical illness and acute illness who do not have confirmed or suspected VTE.

Methods: ASH formed a multidisciplinary guideline panel and applied strict management strategies to minimize potential bias from conflicts of interest. Read More

View Article and Full-Text PDF
February 2021